Search | Clinical Trials Finder

Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions: Retinal and Choroidal Imaging; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Poliomyelitis, Postpoliomyelitis Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1982 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: [18F] GE-180; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Riluzole Oral Soluble film (ROSF) 50 mg; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 17 more

Conditions: C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia
Interventions: Metformin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Amyotrophic Lateral Sclerosis Assessment Questionnaire-40; Other
Lead sponsor: TidalHealth, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Salisbury, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Brain Computer Interface for Wheelchair Tilt Control; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Trehalose; Drug
Lead sponsor: Seelos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 21
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 16 more

Conditions: Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions: Advanced multi-component meditation practice; Behavioral
Lead sponsor: Tobias Moeller-Bertram; Industry
Eligibility: 21 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Palm Desert, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: P300 Brain Computer Interface Keyboard; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: 7 Tesla MRI; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: nL-CHCHD-001; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD), PPA Syndrome, Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis (ALS), Oligosymptomatic PSP (oPSP), Corticobasal Syndrome (CBS)
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,489 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more

Conditions: Sporadic Amyotrophic Lateral Sclerosis
Interventions: Mexiletine, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Phoenix, Arizona • Orange, California • Augusta, Georgia + 7 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: TCH346; Drug
Lead sponsor: Novartis; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Zinc and Copper; Drug
Lead sponsor: Phoenix Neurological Associates, LTD; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ozanezumab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: β-hydroxy-β-methylbutyrate (HMB); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions: Use of Rare Beauty makeup products; Other
Lead sponsor: Casa Colina Hospital and Centers for Healthcare; Other
Eligibility: 18 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Pomona, California

Conditions: ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
Interventions: Tocilizumab, Placebo; Drug · Other
Lead sponsor: Barrow Neurological Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Kansas City, Kansas • Boston, Massachusetts + 2 more

Conditions: Amyotrophic Lateral Sclerosis, Dysphagia, Dyspnea, Respiration Disorders
Interventions: Experimental expiratory muscle strength training (EMST), Sham expiratory muscle strength training (EMST); Device
Lead sponsor: Cara Donohue; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: Astaxanthin, Protandim, Melatonin, MitoQ; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: nL-TARDB-006; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Search by objective public record fields.

Retinal Imaging in Neurodegenerative Disease

Study of "Post-Polio Syndrome"

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth

An In-home Study of Brain Computer Interfaces

Intermediate-Sized Expanded Access Study

Quest to Analyze One Thousand Humans Meditating

A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis

Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS)

Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)

Safety Study of High Doses of Zinc in ALS Patients

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

A Trial of Tocilizumab in ALS Subjects

Fatigue in Patients With Amyotrophic Lateral Sclerosis

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS